SiliqActive Ingredient(s): Brodalumab
FDA Approved: * February 15, 2017
Pharm Company: * VALEANT LUXEMBOURG
Category: Immune System
Brodalumab (trade name Siliq in the US and Kyntheum in Europe) is a human monoclonal antibody designed for the treatment of inflammatory diseases. In February 2017 it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments. Mechanism of action Brodalumab binds to the interleukin-17 receptor and so prevents interleukin 17 (IL-17) from activating the receptor. This me... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.
Siliq 210 mg Subcutaneous InjectionNDC: 0187-0004
Valeant Pharmaceuticals North America LLC